Detalles de la búsqueda
1.
A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes After Acute Myocardial Infarction.
Circulation
; 146(16): 1196-1206, 2022 10 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-36030390
2.
Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial.
Lancet
; 392(10152): 1036-1046, 2018 09 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-30158069
3.
Bleeding Risk Prediction in Patients Treated with Antithrombotic Drugs According to the Anatomic Site of Bleeding, Indication for Treatment, and Time Since Treatment Initiation.
TH Open
; 8(1): e121-e131, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-38505564
4.
Bleeding Outcomes in Patients Treated With Asundexian in Phase II Trials.
J Am Coll Cardiol
; 83(6): 669-678, 2024 Feb 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-38325992
5.
Budget Impact of Appropriate Low-Dose Aspirin Use for Primary and Secondary Cardiovascular Event Prevention in the Managed Care Setting.
J Manag Care Spec Pharm
; 24(11): 1102-1111, 2018 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-30362916
6.
Antiplatelet effects of aspirin with phytosterols: comparison with non-enteric coated aspirin alone.
Thromb Res
; 126(5): 384-5, 2010 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-19446864
Resultados
1 -
6
de 6
1
Próxima >
>>